ClinicalTrials.gg
TerminatedNCT06171789Updated Oct 29, 2026Results posted

PRO1107 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of GEN1107 in Endometrial Cancer, Ovarian Cancer and Triple Negative Breast Cancer, sponsored by Genmab. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
Updated Oct 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
399th of 591
33 · median 60
Started
2024
with 45 others
Phase 1/2
85 of 715
42 open now
Registered
567th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 399th largest by enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2024, is one of 85 in phase 1/2, and was the 567th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

Read the detailed description

This is a Phase 1/2 study of GEN1107, a protein tyrosine K 7 (PTK7) targeted antibody-drug conjugate (ADC), to evaluate the safety, tolerability, PK, and antitumor activity of GEN1107 in participants with advanced solid tumors, including ovarian cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastroesophageal cancer, and urothelial cancer. This study consists of 2 parts, Part A: Dose Escalation and Dose Level Expansion and Part B: Tumor Specific Expansion.

In Part A, GEN1107 will be administered in different dosing regimens via intravenous (IV) infusion.

Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from Part A in up to 4 different tumor-specific cohorts of up to 40 participants per cohort.

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

03

Conditions studied

  • Endometrial Cancer
  • Ovarian Cancer
  • Triple Negative Breast Cancer
  • GastroEsophageal Cancer
  • Non-small Cell Lung Cancer
  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • confirmed diagnosis of one of the following tumor types:
  • Ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)
  • Endometrial cancer (any subtype excluding sarcoma)
  • Triple negative breast cancer (TNBC)
  • Non-small cell lung cancer (NSCLC)

    • or unresectable locally advanced, recurrent, disease not amenable to further local therapy following prior systemic therapies known to confer clinical benefit.

Part B:

  • Participants must have a histologically or cytologically confirmed metastatic or unresectable solid as specified below:

    • Ovarian cancer
    • TNBC
    • Endometrial cancer
    • NSCLC
  • at baseline as defined per , Version 1.1

Exclusion criteria

Exclusion Criteria

  • Prior treatment with anti-PTK7-directed therapy.
  • Had progressive disease as best response while on treatment with an auristatin (eg, a vedotin or pelidotin)- based ADC as the most recent .
  • History of another within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of or death (eg, 5-year overall survival [OS] ≥90%)
  • Known active central nervous system metastases, including carcinomatous meningitis. Participants with may participate provided the metastases have been treated and are stable for at least 4 weeks prior to the first dose of study drug, they have no new or enlarging brain metastases and have discontinued prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with a history of brain metastases, suspected new brain metastases, or a diagnosis of NSCLC or breast cancer should have a computed tomography (CT)/ magnetic resonance imaging (MRI) scan of the brain at screening.
  • Participants with active or chronic corneal disorders, history of corneal transplantation, or any corneal disease that prevents adequate monitoring of potential drug-induced keratopathy. Note: Participants with other active ocular conditions requiring ongoing therapy and/or monitoring must be discussed with the sponsor prior to enrollment.

Additional protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    GEN1107

    GEN1107 monotherapy in escalating doses in Part A and at the dose level in Part B.

    Drug: GEN1107

Interventions

  • DrugGEN1107

    IV infusion of GEN1107

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event (AE) with an onset date or worsening grade within the on-treatment period. An AE was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to approximately 1 year, 7 months

  2. Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as any of the following during the DLT evaluation period (up to 28 days) if considered not clearly and incontrovertibly due to the underlying disease or extraneous causes by either the Investigator or the Sponsor: any death not clearly due to the underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity, with exceptions per protocol, the abnormality indicative of drug-induced liver injury as defined by Hy's Law criteria, Grade 4 anemia or Grade 3 anemia lasting \>7 days (transfusions permitted), Grade 4 neutropenia lasting \>7 days, Grade 4 thrombocytopenia lasting \>7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/microliters \[µL\] with a single oral temperature measurement of ≥ 38.3 degrees Celsius \[ºC\] \[101 degrees Fahrenheit \[ºF\]\] or a temperature of ≥ 38ºC \[100.4ºF\] sustained over a 1-hour period).

    Time frame: Up to 28 days

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria as assessed by the investigator. CR was defined as disappearance of all target and non-target tumor lesions, reduction in short axis to \<10 millimeters (mm) in all pathological target and non-target lymph nodes and normalization of tumor marker level (if applicable). PR was defined as ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confidence interval (CI) is based on the Clopper-Pearson method.

    Time frame: Up to approximately 1 year, 7 months

  2. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR per RECIST v1.1 criteria. CI is based on the Clopper-Pearson method.

    Time frame: Up to approximately 1 year, 7 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.

    Time frame: Up to approximately 1 year, 7 months

  4. Duration of Objective Response (DOR)

    DOR was defined as the time from the first documentation of an objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.

    Time frame: Up to approximately 1 year, 7 months

  5. Area Under the Curve (AUC) of GEN1107 Related Analytes

    Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated monomethyl auristatin E \[MMAE\], unconjugated MMAE).

    Time frame: For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, end of infusion (EOI), 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles). For 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)

  6. Maximum Concentration (Cmax) of GEN1107 Related Analytes

    Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

    Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose, EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles)

  7. Time to Maximum Concentration (Tmax) of GEN1107 Related Analytes

    Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

    Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only:Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose, EOI,72,168, 336, 504 hours post-2nd dose (28 day cycles)

  8. Apparent Terminal Half-life (t1/2) of GEN1107 Related Analytes

    Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

    Time frame: For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, EOI, 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles), for 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)

  9. Trough Concentration (Ctrough) of GEN1107 Related Analytes

    Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE). The number of participants analyzed reflects participants with evaluable PK data at the relevant sampling timepoint. Where 0 participants are reported, this indicates that no participants had evaluable data for that parameter/timepoint or that the assessment was not applicable for the dosing regimen.

    Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336, 504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles).

  10. Number of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer

    For participants with ovarian cancer, a CA-125 response per the GCIG criteria was defined as a ≥50% reduction in CA-125 levels from baseline. The following must also have applied: CA-125 levels must have been ≥2.0 times the upper limit of normal (ULN) within 2 weeks before starting treatment, and the CA-125 response must have been confirmed and maintained for at least 28 days. The analysis included participants with ovarian cancer who were evaluable for CA-125 response. Evaluable participants had baseline CA-125 ≥2× the upper limit of normal (ULN) within 14 days before the first dose and at least one post-baseline assessment. Participants who did not meet these criteria were excluded from the analysis. For arms with an overall number analyzed of 0, no participants met the protocol-defined evaluability criteria.

    Time frame: Up to approximately 1 year, 7 months

07

Results

Posted Oct 29, 2026
Limitations and caveats
This trial was planned to be conducted in 2 parts: Part A, dose escalation and dose level expansion; and Part B, tumor-specific expansion. The trial was terminated during Part A dose escalation and did not proceed to Part A dose level expansion or Part B.

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Started22456482
Received at least 1 dose of treatment22456482
Completed01222100
Not completed21234382
Withdrew: Death11213372
Withdrew: Study termination by sponsor10020010
Withdrew: Progressive disease00001000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event (AE) with an onset date or worsening grade within the on-treatment period. An AE was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Number of Participants With Treatment-emergent Adverse Events (TEAEs)22455482
PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as any of the following during the DLT evaluation period (up to 28 days) if considered not clearly and incontrovertibly due to the underlying disease or extraneous causes by either the Investigator or the Sponsor: any death not clearly due to the underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity, with exceptions per protocol, the abnormality indicative of drug-induced liver injury as defined by Hy's Law criteria, Grade 4 anemia or Grade 3 anemia lasting \>7 days (transfusions permitted), Grade 4 neutropenia lasting \>7 days, Grade 4 thrombocytopenia lasting \>7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/microliters \[µL\] with a single oral temperature measurement of ≥ 38.3 degrees Celsius \[ºC\] \[101 degrees Fahrenheit \[ºF\]\] or a temperature of ≥ 38ºC \[100.4ºF\] sustained over a 1-hour period).

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Number of Participants With Dose Limiting Toxicities (DLTs)00000001
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who achieved partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria as assessed by the investigator. CR was defined as disappearance of all target and non-target tumor lesions, reduction in short axis to \<10 millimeters (mm) in all pathological target and non-target lymph nodes and normalization of tumor marker level (if applicable). PR was defined as ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confidence interval (CI) is based on the Clopper-Pearson method.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Objective Response Rate (ORR)0 (0.00 to 84.19)0 (0.00 to 84.19)0 (0.00 to 60.24)0 (0.00 to 52.18)0 (0.00 to 52.18)0 (0.00 to 70.76)28.6 (3.67 to 70.96)—
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR per RECIST v1.1 criteria. CI is based on the Clopper-Pearson method.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Disease Control Rate (DCR)50.0 (1.26 to 98.74)100.0 (15.81 to 100.00)75.0 (19.41 to 99.37)100.0 (47.82 to 100.00)40.0 (5.27 to 85.34)66.7 (9.43 to 99.16)71.4 (29.04 to 96.33)—
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Progression-free Survival (PFS)NA (1.28 to NA)4.09 (4.07 to NA)2.63 (1.38 to NA)7.43 (2.73 to NA)1.40 (0.89 to NA)1.58 (0.85 to NA)2.12 (1.18 to 5.22)1.79 (1.74 to NA)
SecondaryDuration of Objective Response (DOR)

DOR was defined as the time from the first documentation of an objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Median · months
Duration of Objective Response (DOR)
monthsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Duration of Objective Response (DOR)——————NA (2.63 to NA)—
SecondaryArea Under the Curve (AUC) of GEN1107 Related Analytes

Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated monomethyl auristatin E \[MMAE\], unconjugated MMAE).

Time frame:
For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, end of infusion (EOI), 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles). For 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
Reported as:
Geometric mean · day*ng/mL
Area Under the Curve (AUC) of GEN1107 Related Analytes
day*ng/mLDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Total antibody Cycle 1 Day 110413.9366 ± 27.020475.6211 ± 9.254719.5854 ± 12.381085.8506 ± 27.176868.7913 ± 30.693621.6326 ± 3.1103016.5975 ± 20.7—
Total antibody Cycle 1 Day 8———————99589.6900
Conjugated MMAE Cycle 1 Day 1355.9793 ± 17.8750.4199 ± 0.61621.6469 ± 12.32535.3404 ± 17.62521.2133 ± 27.52771.3718 ± 11.53441.2499 ± 22.1—
Conjugated MMAE Cycle 1 Day 8———————2612.6760
Unconjugated MMAE Cycle 1 Day 16.362011.399027.4365 ± 77.021.8609 ± 104.533.8916 ± 88.170.770056.0742 ± 33.8—
Unconjugated MMAE Cycle 1 Day 8———————29.4870
SecondaryMaximum Concentration (Cmax) of GEN1107 Related Analytes

Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

Time frame:
Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose, EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles)
Reported as:
Geometric mean · nanograms per milliliter (ng/ml)
Maximum Concentration (Cmax) of GEN1107 Related Analytes
nanograms per milliliter (ng/ml)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Total antibody Cycle 1 Day 16706.176 ± 17.59815.312 ± 12.318217.621 ± 8.119896.525 ± 24.619157.244 ± 25.526370.367 ± 11.427602.448 ± 22.619439.621 ± 13.2
Total antibody Cycle 1 Day 8———————19725.228 ± 25.3
Conjugated MMAE Cycle 1 Day 1184.0 ± 23.7323.8 ± 5.2553.6 ± 4.1616.3 ± 10.5646.2 ± 13.6856.0 ± 8.4952.9 ± 22.0585.1 ± 18.5
Conjugated MMAE Cycle 1 Day 8———————573.8 ± 23.5
Unconjugated MMAE Cycle 1 Day 10.3675 ± 109.71.0147 ± 11.51.8422 ± 75.31.7929 ± 92.82.7091 ± 66.76.0886 ± 15.64.7850 ± 39.91.9672 ± 39.8
Unconjugated MMAE Cycle 1 Day 8———————2.2826 ± 6.5
SecondaryTime to Maximum Concentration (Tmax) of GEN1107 Related Analytes

Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

Time frame:
Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only:Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose, EOI,72,168, 336, 504 hours post-2nd dose (28 day cycles)
Reported as:
Geometric mean · days
Time to Maximum Concentration (Tmax) of GEN1107 Related Analytes
daysDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Total antibody Cycle 1 Day 10.0245 ± 2.90.0563 ± 94.50.0696 ± 89.90.0407 ± 65.30.0765 ± 235.20.0524 ± 68.30.0510 ± 65.30.0397 ± 17.9
Total antibody Cycle 1 Day 8———————0.0390 ± 23.8
Conjugated MMAE Cycle 1 Day 10.0245 ± 2.90.0283 ± 17.60.0277 ± 16.30.0407 ± 65.30.0617 ± 253.70.0524 ± 68.30.0553 ± 71.00.0397 ± 17.9
Conjugated MMAE Cycle 1 Day 8———————0.0390 ± 23.8
Unconjugated MMAE Cycle 1 Day 10.9414 ± 6.81.9018 ± 5.93.3200 ± 59.14.6158 ± 43.14.1395 ± 100.04.3798 ± 44.34.7327 ± 62.32.9658 ± 1.7
Unconjugated MMAE Cycle 1 Day 8———————3.1393 ± 69.9
SecondaryApparent Terminal Half-life (t1/2) of GEN1107 Related Analytes

Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).

Time frame:
For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, EOI, 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles), for 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
Reported as:
Geometric mean · days
Apparent Terminal Half-life (t1/2) of GEN1107 Related Analytes
daysDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Total antibody Cycle 1 Day 11.3793 ± 2.11.3869 ± 8.72.0788 ± 19.23.2138 ± 23.83.2028 ± 36.32.0597 ± 14.72.8470 ± 37.3—
Total antibody Cycle 1 Day 8———————2.3480
Conjugated MMAE Cycle 1 Day 11.7719 ± 30.53.7028 ± 87.23.6406 ± 48.64.0874 ± 23.03.9962 ± 24.62.9990 ± 11.93.9973 ± 26.7—
Conjugated MMAE Cycle 1 Day 8———————3.3720
Unconjugated MMAE Cycle 1 Day 13.97803.99904.9978 ± 21.76.1131 ± 35.55.9716 ± 6.36.57305.4111 ± 12.2—
Unconjugated MMAE Cycle 1 Day 8———————5.3300
SecondaryTrough Concentration (Ctrough) of GEN1107 Related Analytes

Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE). The number of participants analyzed reflects participants with evaluable PK data at the relevant sampling timepoint. Where 0 participants are reported, this indicates that no participants had evaluable data for that parameter/timepoint or that the assessment was not applicable for the dosing regimen.

Time frame:
Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336, 504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles).
Reported as:
Geometric mean · ng/mL
Trough Concentration (Ctrough) of GEN1107 Related Analytes
ng/mLDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Total antibody Cycle 1 Day 1————399.410—174.910—
Conjugated MMAE Cycle 1 Day 1—2.6605.077 ± 97.98.994 ± 68.99.627 ± 94.47.3307.292 ± 55.5—
Conjugated MMAE Cycle Cycle 1 Day 8———————5.820
Unconjugated MMAE Cycle 1 Day 10.03500.07700.2749 ± 102.70.2329 ± 79.60.3632 ± 58.31.11000.5415 ± 55.0—
Unconjugated MMAE Cycle 1 Day 8———————0.3060
SecondaryNumber of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer

For participants with ovarian cancer, a CA-125 response per the GCIG criteria was defined as a ≥50% reduction in CA-125 levels from baseline. The following must also have applied: CA-125 levels must have been ≥2.0 times the upper limit of normal (ULN) within 2 weeks before starting treatment, and the CA-125 response must have been confirmed and maintained for at least 28 days. The analysis included participants with ovarian cancer who were evaluable for CA-125 response. Evaluable participants had baseline CA-125 ≥2× the upper limit of normal (ULN) within 14 days before the first dose and at least one post-baseline assessment. Participants who did not meet these criteria were excluded from the analysis. For arms with an overall number analyzed of 0, no participants met the protocol-defined evaluability criteria.

Time frame:
Up to approximately 1 year, 7 months
Reported as:
Count of participants · Participants
Number of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer
ParticipantsDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
Number of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer——00—010

Adverse events

Collected over Up to approximately 1 year, 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: GEN1107 8 mg/m^21/2 (50%)0/2 (0%)2/2 (100%)
Dose Escalation: GEN1107 15 mg/m^21/2 (50%)1/2 (50%)2/2 (100%)
Dose Escalation: GEN1107 30 mg/m^22/4 (50%)0/4 (0%)4/4 (100%)
Dose Escalation: GEN1107 37.5 mg/m^21/5 (20%)1/5 (20%)5/5 (100%)
Dose Escalation: GEN1107 45 mg/m^24/6 (66.7%)2/6 (33.3%)5/6 (83.3%)
Dose Escalation: GEN1107 52.5 mg/m^23/4 (75%)2/4 (50%)4/4 (100%)
Dose Escalation: GEN1107 60 mg/m^27/8 (87.5%)4/8 (50%)8/8 (100%)
Dose Escalation: GEN1107 30 mg/m^2 2Q4W2/2 (100%)2/2 (100%)2/2 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
PneumonitisRespiratory, thoracic and mediastinal disorders0/20/20/40/50/60/40/81/2
EmbolismVascular disorders0/20/20/40/51/60/40/81/2
Rash maculo-papularSkin and subcutaneous tissue disorders0/20/20/40/50/60/40/81/2
Ischaemic strokeNervous system disorders0/21/20/40/50/60/40/80/2
HypercalcaemiaMetabolism and nutrition disorders0/20/20/40/50/61/40/80/2
PeritonitisInfections and infestations0/20/20/40/50/61/40/80/2
Gastroenteritis norovirusInfections and infestations0/20/20/41/50/60/40/80/2
Acute kidney injuryRenal and urinary disorders0/20/20/40/51/60/40/80/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/20/20/40/50/60/41/80/2
HypoxiaRespiratory, thoracic and mediastinal disorders0/20/20/40/50/60/41/80/2
Most frequent other events
Showing 10 of 106
Most frequent other events
EventDose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4W
HypokalaemiaMetabolism and nutrition disorders0/22/20/42/51/61/42/81/2
NauseaGastrointestinal disorders2/22/22/41/52/62/44/81/2
Neutrophil count decreasedInvestigations0/21/23/42/52/62/45/80/2
AlopeciaSkin and subcutaneous tissue disorders1/20/23/43/54/62/46/81/2
FatigueGeneral disorders and administration site conditions1/21/21/41/51/63/44/81/2
DysgeusiaNervous system disorders0/20/20/43/50/60/40/80/2
OnychomadesisSkin and subcutaneous tissue disorders0/21/20/40/50/60/40/80/2
Alanine aminotransferase increasedInvestigations0/20/20/41/50/60/40/81/2
KeratitisEye disorders1/20/20/41/51/61/42/80/2
Musculoskeletal painMusculoskeletal and connective tissue disorders0/20/20/40/50/60/40/81/2

Baseline characteristics

All-treated Participants Analysis Set included all participants who received any amount of GEN1107.

Age, Categorical
Age, Categorical(Participants)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
<=18 years000000000
Between 18 and 65 years2243424122
>=65 years0002224111
Age, Continuous
Age, Continuous(years)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
Mean55 ± 2.859 ± 1.454.5 ± 10.561.4 ± 7.159.5 ± 7.460.5 ± 14.265 ± 10.959 ± 8.560.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
Female2244234223
Male0001414010
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
Hispanic or Latino000100102
Missing100000203
Not Hispanic or Latino1244645228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
American Indian or Alaska Native000000000
Asian Indian000000000
Asian Other000001001
Black or African American000000000
Chinese000000000
Japanese000000000
Malay000000000
Missing000000000
Native Hawaiian or Other Pacific Islander000000000
Not Reported000000011
Other000000000
White2245638131
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation: GEN1107 8 mg/m^2Dose Escalation: GEN1107 15 mg/m^2Dose Escalation: GEN1107 30 mg/m^2Dose Escalation: GEN1107 37.5 mg/m^2Dose Escalation: GEN1107 45 mg/m^2Dose Escalation: GEN1107 52.5 mg/m^2Dose Escalation: GEN1107 60 mg/m^2Dose Escalation: GEN1107 30 mg/m^2 2Q4WTotal
China000001001
United States2245638232
08

Study locations

7 sites
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34236, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • START Mountain Cancer Center
    Salt Lake City, Utah 78229, United States
  • Institution of Hunan Cancer Hospital
    Changsha, Hunan 410013, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Aug 2025, 19 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 15, 2023
StartActual
Jan 3, 2024
Primary completionActual
Aug 18, 2025
CompletionActual
Aug 18, 2025
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
  • EditedNumber of Participants withWith Dose Limiting Toxicities (DLTs)Time frame: Day 1 up to a maximum of Day 28 → Up to 28 days
Oct 29, 2026
Documents
Secondary outcomes
10 edited
What changed in the outcomes
  • EditedObjective Response Rate (ORR)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
  • EditedDisease Control Rate (DCR)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
  • EditedProgression-free Survival (PFS)Time frame: Up to approximately 18 months → Up to approximately 1 year, 7 months
  • EditedDuration of Objective Response (DOR)Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months → Up to approximately 1 year, 7 months
  • EditedPharmacokinetic Parameter Area Under the Curve (AUC) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, end of infusion (EOI), 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles). For 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
  • EditedPharmacokinetic Parameter Maximum Concentration (Cmax) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose, EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles)
  • EditedPharmacokinetic Parameter Time to Maximum Concentration (Tmax) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only:Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose, EOI,72,168, 336, 504 hours post-2nd dose (28 day cycles)
  • EditedPharmacokinetic Parameter Apparent Terminal Half-life (t1/2) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, EOI, 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles), for 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
  • EditedPharmacokinetic Parameter Trough Concentration (Ctrough) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336, 504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles).
  • EditedNumber of Participants With Cancer Antigen 125 (CA-125) Response perPer Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian CancerTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of Participants withWith Treatment-emergent Adverse Events (TEAEs)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
    • EditedNumber of Participants withWith Dose Limiting Toxicities (DLTs)Time frame: Day 1 up to a maximum of Day 28 → Up to 28 days
    Secondary outcomes 10 edited
    What changed in the outcomes
    • EditedObjective Response Rate (ORR)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
    • EditedDisease Control Rate (DCR)Time frame: Through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
    • EditedProgression-free Survival (PFS)Time frame: Up to approximately 18 months → Up to approximately 1 year, 7 months
    • EditedDuration of Objective Response (DOR)Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months → Up to approximately 1 year, 7 months
    • EditedPharmacokinetic Parameter Area Under the Curve (AUC) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, end of infusion (EOI), 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles). For 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
    • EditedPharmacokinetic Parameter Maximum Concentration (Cmax) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose, EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles)
    • EditedPharmacokinetic Parameter Time to Maximum Concentration (Tmax) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only:Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose, EOI,72,168, 336, 504 hours post-2nd dose (28 day cycles)
    • EditedPharmacokinetic Parameter Apparent Terminal Half-life (t1/2) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, EOI, 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles), for 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
    • EditedPharmacokinetic Parameter Trough Concentration (Ctrough) forof GEN1107 Related AnalytesTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336, 504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles).
    • EditedNumber of Participants With Cancer Antigen 125 (CA-125) Response perPer Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian CancerTime frame: Varying timepoints through end of treatment, up to approximately 1 year → Up to approximately 1 year, 7 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06171789
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 3, 2024
Primary completion
Aug 18, 2025
Completion
Aug 18, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion